HBV and HCV prevalence and viraemia in HIV‐positive and HIV‐negative pregnant women in Abidjan, Côte d'Ivoire: The ANRS 1236 study
Identifieur interne : 000918 ( Istex/Corpus ); précédent : 000917; suivant : 000919HBV and HCV prevalence and viraemia in HIV‐positive and HIV‐negative pregnant women in Abidjan, Côte d'Ivoire: The ANRS 1236 study
Auteurs : François Rouet ; Marie-Laure Chaix ; André Inwoley ; Philippe Msellati ; Ida Viho ; Patrice Combe ; Valériane Leroy ; François Dabis ; Christine RouziouxSource :
- Journal of Medical Virology [ 0146-6615 ] ; 2004-09.
English descriptors
- KwdEn :
- Abidjan, African countries, Algorithm, Anrs, Assay, Bayer diagnostics, Biphasic distribution, Burkina faso, Cell count, Centre hospitalier universitaire, Chronic hepatitis, Clin, Cobas amplicor, Cote, Eias, Enzyme immunoassays, Genotype, Grant sponsor, Hbsag, Hepatitis, Hepatitis viruses, High frequency, Human virus, Human virus infection, Industrialised countries, Infection, Ingen, Ingen technique, Ingen test, Ivoirian women, Little information, Medical management, Microbiol, Murex, Murex assay, Negative women, Ortho, Ortho assay, Parallel algorithm, Positive results, Positive samples, Positive specimens, Pregnant women, Present study, Prevalence, Primary screening, Riba, Serum samples, Southern tanzania, Study group, Study groups, Supplementary assays, Uninfected women, Univariate kernel density estimation, Universite victor segalen, Vast majority, Viral hepatitis, Virol, Virus infection, West africa.
- Teeft :
- Abidjan, African countries, Algorithm, Anrs, Assay, Bayer diagnostics, Biphasic distribution, Burkina faso, Cell count, Centre hospitalier universitaire, Chronic hepatitis, Clin, Cobas amplicor, Cote, Eias, Enzyme immunoassays, Genotype, Grant sponsor, Hbsag, Hepatitis, Hepatitis viruses, High frequency, Human virus, Human virus infection, Industrialised countries, Infection, Ingen, Ingen technique, Ingen test, Ivoirian women, Little information, Medical management, Microbiol, Murex, Murex assay, Negative women, Ortho, Ortho assay, Parallel algorithm, Positive results, Positive samples, Positive specimens, Pregnant women, Present study, Prevalence, Primary screening, Riba, Serum samples, Southern tanzania, Study group, Study groups, Supplementary assays, Uninfected women, Univariate kernel density estimation, Universite victor segalen, Vast majority, Viral hepatitis, Virol, Virus infection, West africa.
Abstract
A retrospective survey estimating the prevalence of hepatitis viruses B (HBV) and C (HCV) was conducted on samples taken in 1,002 African pregnant women (501 diagnosed as HIV‐1 positive and 501 HIV‐1 negative) participating in a clinical trial program conducted in Abidjan, Côte d'Ivoire (West Africa). Hepatitis B markers studied were HBs antigen (HBsAg), and if positive, HBe antigen/anti‐HBe antibodies and HBV DNA. Two third generation (G3) HCV enzyme immunoassays (EIAs) were used for primary HCV screening. All anti‐HCV antibody‐positive sera were assessed further with supplementary assays (one another G3 EIA, RIBA 3.0, and HCV RNA). HCV genotypes were also determined. HBsAg was found in a similar proportion among HIV‐positive (45/499, 9.0%, 95% confidence interval [95% CI], 6.6–11.9) and HIV‐negative (40/498, 8.0%, 95% CI, 5.8–10.8) women (P = 0.58). The diagnosis of chronic hepatitis B, based on HBV DNA positive results, was more frequent in HIV‐positive women (26.7%), compared to HIV‐negative women (9.4%) (P = 0.06). In the case of hepatitis C infection, after supplementary testing allowing the elimination of frequent false‐positive screening results, a prevalence rate of about 1% was found, both in HIV‐positive (6/501, 1.2%, 95% CI, 0.44–2.59) and HIV‐negative (4/501, 0.8%, 95% CI, 0.22–2.03) women (P = 0.53). Of the 10 samples confirmed positive and assessed for HCV RNA, eight (80%) were viraemic and belonged to HCV genotypes 1 or 2. The relative high frequency of HIV/HBV coinfection in Côte d'Ivoire emphasises the need for monitoring the risk of hepatotoxicity by antiretroviral therapy in such patients. We propose an accurate and cost‐efficient algorithm for HCV diagnosis in Africa. J. Med. Virol. 74:34–40, 2004. © 2004 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/jmv.20143
Links to Exploration step
ISTEX:3E9C3E3ED2AF32E19C12B373783F2B62F3082F05Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">HBV and HCV prevalence and viraemia in HIV‐positive and HIV‐negative pregnant women in Abidjan, Côte d'Ivoire: The ANRS 1236 study</title><author><name sortKey="Rouet, Francois" sort="Rouet, Francois" uniqKey="Rouet F" first="François" last="Rouet">François Rouet</name><affiliation><mods:affiliation>CeDReS, CHU de Treichville, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation><affiliation><mods:affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation><affiliation><mods:affiliation>CeDReS, Programme PAC‐CI, CHU de Treichville, BP V3 Abidjan, Côte d'Ivoire.===</mods:affiliation></affiliation></author><author><name sortKey="Chaix, Marie Aure" sort="Chaix, Marie Aure" uniqKey="Chaix M" first="Marie-Laure" last="Chaix">Marie-Laure Chaix</name><affiliation><mods:affiliation>Laboratoire de Virologie, CHU Necker, EA 3620 Université René Descartes, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Inwoley, Andre" sort="Inwoley, Andre" uniqKey="Inwoley A" first="André" last="Inwoley">André Inwoley</name><affiliation><mods:affiliation>CeDReS, CHU de Treichville, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation><affiliation><mods:affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Msellati, Philippe" sort="Msellati, Philippe" uniqKey="Msellati P" first="Philippe" last="Msellati">Philippe Msellati</name><affiliation><mods:affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Viho, Ida" sort="Viho, Ida" uniqKey="Viho I" first="Ida" last="Viho">Ida Viho</name><affiliation><mods:affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Combe, Patrice" sort="Combe, Patrice" uniqKey="Combe P" first="Patrice" last="Combe">Patrice Combe</name><affiliation><mods:affiliation>CeDReS, CHU de Treichville, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation><affiliation><mods:affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Leroy, Valeriane" sort="Leroy, Valeriane" uniqKey="Leroy V" first="Valériane" last="Leroy">Valériane Leroy</name><affiliation><mods:affiliation>INSERM U593, ISPED, Université Victor Segalen, Bordeaux, France</mods:affiliation></affiliation></author><author><name sortKey="Dabis, Francois" sort="Dabis, Francois" uniqKey="Dabis F" first="François" last="Dabis">François Dabis</name><affiliation><mods:affiliation>INSERM U593, ISPED, Université Victor Segalen, Bordeaux, France</mods:affiliation></affiliation></author><author><name sortKey="Rouzioux, Christine" sort="Rouzioux, Christine" uniqKey="Rouzioux C" first="Christine" last="Rouzioux">Christine Rouzioux</name><affiliation><mods:affiliation>Laboratoire de Virologie, CHU Necker, EA 3620 Université René Descartes, Paris, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3E9C3E3ED2AF32E19C12B373783F2B62F3082F05</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/jmv.20143</idno><idno type="url">https://api.istex.fr/document/3E9C3E3ED2AF32E19C12B373783F2B62F3082F05/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000918</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000918</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">HBV and HCV prevalence and viraemia in HIV‐positive and HIV‐negative pregnant women in Abidjan, Côte d'Ivoire: The ANRS 1236 study</title><author><name sortKey="Rouet, Francois" sort="Rouet, Francois" uniqKey="Rouet F" first="François" last="Rouet">François Rouet</name><affiliation><mods:affiliation>CeDReS, CHU de Treichville, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation><affiliation><mods:affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation><affiliation><mods:affiliation>CeDReS, Programme PAC‐CI, CHU de Treichville, BP V3 Abidjan, Côte d'Ivoire.===</mods:affiliation></affiliation></author><author><name sortKey="Chaix, Marie Aure" sort="Chaix, Marie Aure" uniqKey="Chaix M" first="Marie-Laure" last="Chaix">Marie-Laure Chaix</name><affiliation><mods:affiliation>Laboratoire de Virologie, CHU Necker, EA 3620 Université René Descartes, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Inwoley, Andre" sort="Inwoley, Andre" uniqKey="Inwoley A" first="André" last="Inwoley">André Inwoley</name><affiliation><mods:affiliation>CeDReS, CHU de Treichville, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation><affiliation><mods:affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Msellati, Philippe" sort="Msellati, Philippe" uniqKey="Msellati P" first="Philippe" last="Msellati">Philippe Msellati</name><affiliation><mods:affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Viho, Ida" sort="Viho, Ida" uniqKey="Viho I" first="Ida" last="Viho">Ida Viho</name><affiliation><mods:affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Combe, Patrice" sort="Combe, Patrice" uniqKey="Combe P" first="Patrice" last="Combe">Patrice Combe</name><affiliation><mods:affiliation>CeDReS, CHU de Treichville, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation><affiliation><mods:affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Leroy, Valeriane" sort="Leroy, Valeriane" uniqKey="Leroy V" first="Valériane" last="Leroy">Valériane Leroy</name><affiliation><mods:affiliation>INSERM U593, ISPED, Université Victor Segalen, Bordeaux, France</mods:affiliation></affiliation></author><author><name sortKey="Dabis, Francois" sort="Dabis, Francois" uniqKey="Dabis F" first="François" last="Dabis">François Dabis</name><affiliation><mods:affiliation>INSERM U593, ISPED, Université Victor Segalen, Bordeaux, France</mods:affiliation></affiliation></author><author><name sortKey="Rouzioux, Christine" sort="Rouzioux, Christine" uniqKey="Rouzioux C" first="Christine" last="Rouzioux">Christine Rouzioux</name><affiliation><mods:affiliation>Laboratoire de Virologie, CHU Necker, EA 3620 Université René Descartes, Paris, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Medical Virology</title><title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title><idno type="ISSN">0146-6615</idno><idno type="eISSN">1096-9071</idno><imprint><biblScope unit="vol">74</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="34">34</biblScope><biblScope unit="page" to="40">40</biblScope><biblScope unit="page-count">7</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-09">2004-09</date></imprint><idno type="ISSN">0146-6615</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0146-6615</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abidjan</term><term>African countries</term><term>Algorithm</term><term>Anrs</term><term>Assay</term><term>Bayer diagnostics</term><term>Biphasic distribution</term><term>Burkina faso</term><term>Cell count</term><term>Centre hospitalier universitaire</term><term>Chronic hepatitis</term><term>Clin</term><term>Cobas amplicor</term><term>Cote</term><term>Eias</term><term>Enzyme immunoassays</term><term>Genotype</term><term>Grant sponsor</term><term>Hbsag</term><term>Hepatitis</term><term>Hepatitis viruses</term><term>High frequency</term><term>Human virus</term><term>Human virus infection</term><term>Industrialised countries</term><term>Infection</term><term>Ingen</term><term>Ingen technique</term><term>Ingen test</term><term>Ivoirian women</term><term>Little information</term><term>Medical management</term><term>Microbiol</term><term>Murex</term><term>Murex assay</term><term>Negative women</term><term>Ortho</term><term>Ortho assay</term><term>Parallel algorithm</term><term>Positive results</term><term>Positive samples</term><term>Positive specimens</term><term>Pregnant women</term><term>Present study</term><term>Prevalence</term><term>Primary screening</term><term>Riba</term><term>Serum samples</term><term>Southern tanzania</term><term>Study group</term><term>Study groups</term><term>Supplementary assays</term><term>Uninfected women</term><term>Univariate kernel density estimation</term><term>Universite victor segalen</term><term>Vast majority</term><term>Viral hepatitis</term><term>Virol</term><term>Virus infection</term><term>West africa</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Abidjan</term><term>African countries</term><term>Algorithm</term><term>Anrs</term><term>Assay</term><term>Bayer diagnostics</term><term>Biphasic distribution</term><term>Burkina faso</term><term>Cell count</term><term>Centre hospitalier universitaire</term><term>Chronic hepatitis</term><term>Clin</term><term>Cobas amplicor</term><term>Cote</term><term>Eias</term><term>Enzyme immunoassays</term><term>Genotype</term><term>Grant sponsor</term><term>Hbsag</term><term>Hepatitis</term><term>Hepatitis viruses</term><term>High frequency</term><term>Human virus</term><term>Human virus infection</term><term>Industrialised countries</term><term>Infection</term><term>Ingen</term><term>Ingen technique</term><term>Ingen test</term><term>Ivoirian women</term><term>Little information</term><term>Medical management</term><term>Microbiol</term><term>Murex</term><term>Murex assay</term><term>Negative women</term><term>Ortho</term><term>Ortho assay</term><term>Parallel algorithm</term><term>Positive results</term><term>Positive samples</term><term>Positive specimens</term><term>Pregnant women</term><term>Present study</term><term>Prevalence</term><term>Primary screening</term><term>Riba</term><term>Serum samples</term><term>Southern tanzania</term><term>Study group</term><term>Study groups</term><term>Supplementary assays</term><term>Uninfected women</term><term>Univariate kernel density estimation</term><term>Universite victor segalen</term><term>Vast majority</term><term>Viral hepatitis</term><term>Virol</term><term>Virus infection</term><term>West africa</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A retrospective survey estimating the prevalence of hepatitis viruses B (HBV) and C (HCV) was conducted on samples taken in 1,002 African pregnant women (501 diagnosed as HIV‐1 positive and 501 HIV‐1 negative) participating in a clinical trial program conducted in Abidjan, Côte d'Ivoire (West Africa). Hepatitis B markers studied were HBs antigen (HBsAg), and if positive, HBe antigen/anti‐HBe antibodies and HBV DNA. Two third generation (G3) HCV enzyme immunoassays (EIAs) were used for primary HCV screening. All anti‐HCV antibody‐positive sera were assessed further with supplementary assays (one another G3 EIA, RIBA 3.0, and HCV RNA). HCV genotypes were also determined. HBsAg was found in a similar proportion among HIV‐positive (45/499, 9.0%, 95% confidence interval [95% CI], 6.6–11.9) and HIV‐negative (40/498, 8.0%, 95% CI, 5.8–10.8) women (P = 0.58). The diagnosis of chronic hepatitis B, based on HBV DNA positive results, was more frequent in HIV‐positive women (26.7%), compared to HIV‐negative women (9.4%) (P = 0.06). In the case of hepatitis C infection, after supplementary testing allowing the elimination of frequent false‐positive screening results, a prevalence rate of about 1% was found, both in HIV‐positive (6/501, 1.2%, 95% CI, 0.44–2.59) and HIV‐negative (4/501, 0.8%, 95% CI, 0.22–2.03) women (P = 0.53). Of the 10 samples confirmed positive and assessed for HCV RNA, eight (80%) were viraemic and belonged to HCV genotypes 1 or 2. The relative high frequency of HIV/HBV coinfection in Côte d'Ivoire emphasises the need for monitoring the risk of hepatotoxicity by antiretroviral therapy in such patients. We propose an accurate and cost‐efficient algorithm for HCV diagnosis in Africa. J. Med. Virol. 74:34–40, 2004. © 2004 Wiley‐Liss, Inc.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>cote</json:string><json:string>eias</json:string><json:string>abidjan</json:string><json:string>murex</json:string><json:string>ortho</json:string><json:string>anrs</json:string><json:string>riba</json:string><json:string>ingen</json:string><json:string>hbsag</json:string><json:string>genotype</json:string><json:string>virol</json:string><json:string>clin</json:string><json:string>pregnant women</json:string><json:string>assay</json:string><json:string>west africa</json:string><json:string>microbiol</json:string><json:string>hepatitis</json:string><json:string>positive results</json:string><json:string>positive specimens</json:string><json:string>negative women</json:string><json:string>algorithm</json:string><json:string>high frequency</json:string><json:string>virus infection</json:string><json:string>positive samples</json:string><json:string>ivoirian women</json:string><json:string>biphasic distribution</json:string><json:string>african countries</json:string><json:string>enzyme immunoassays</json:string><json:string>supplementary assays</json:string><json:string>primary screening</json:string><json:string>bayer diagnostics</json:string><json:string>centre hospitalier universitaire</json:string><json:string>chronic hepatitis</json:string><json:string>prevalence</json:string><json:string>industrialised countries</json:string><json:string>study groups</json:string><json:string>parallel algorithm</json:string><json:string>cell count</json:string><json:string>cobas amplicor</json:string><json:string>univariate kernel density estimation</json:string><json:string>present study</json:string><json:string>murex assay</json:string><json:string>ingen test</json:string><json:string>little information</json:string><json:string>vast majority</json:string><json:string>ingen technique</json:string><json:string>grant sponsor</json:string><json:string>serum samples</json:string><json:string>medical management</json:string><json:string>ortho assay</json:string><json:string>uninfected women</json:string><json:string>human virus infection</json:string><json:string>southern tanzania</json:string><json:string>burkina faso</json:string><json:string>hepatitis viruses</json:string><json:string>universite victor segalen</json:string><json:string>study group</json:string><json:string>human virus</json:string><json:string>viral hepatitis</json:string><json:string>infection</json:string></teeft></keywords><author><json:item><name>François Rouet</name><affiliations><json:string>CeDReS, CHU de Treichville, Abidjan, Côte d'Ivoire</json:string><json:string>Programme PAC‐CI, Abidjan, Côte d'Ivoire</json:string><json:string>CeDReS, Programme PAC‐CI, CHU de Treichville, BP V3 Abidjan, Côte d'Ivoire.===</json:string></affiliations></json:item><json:item><name>Marie‐Laure Chaix</name><affiliations><json:string>Laboratoire de Virologie, CHU Necker, EA 3620 Université René Descartes, Paris, France</json:string></affiliations></json:item><json:item><name>André Inwoley</name><affiliations><json:string>CeDReS, CHU de Treichville, Abidjan, Côte d'Ivoire</json:string><json:string>Programme PAC‐CI, Abidjan, Côte d'Ivoire</json:string></affiliations></json:item><json:item><name>Philippe Msellati</name><affiliations><json:string>Programme PAC‐CI, Abidjan, Côte d'Ivoire</json:string></affiliations></json:item><json:item><name>Ida Viho</name><affiliations><json:string>Programme PAC‐CI, Abidjan, Côte d'Ivoire</json:string></affiliations></json:item><json:item><name>Patrice Combe</name><affiliations><json:string>CeDReS, CHU de Treichville, Abidjan, Côte d'Ivoire</json:string><json:string>Programme PAC‐CI, Abidjan, Côte d'Ivoire</json:string></affiliations></json:item><json:item><name>Valériane Leroy</name><affiliations><json:string>INSERM U593, ISPED, Université Victor Segalen, Bordeaux, France</json:string></affiliations></json:item><json:item><name>François Dabis</name><affiliations><json:string>INSERM U593, ISPED, Université Victor Segalen, Bordeaux, France</json:string></affiliations></json:item><json:item><name>Christine Rouzioux</name><affiliations><json:string>Laboratoire de Virologie, CHU Necker, EA 3620 Université René Descartes, Paris, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>HBV</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>HCV</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>HIV‐1 coinfection</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pregnant women</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Côte d'Ivoire</value></json:item></subject><articleId><json:string>JMV20143</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>A retrospective survey estimating the prevalence of hepatitis viruses B (HBV) and C (HCV) was conducted on samples taken in 1,002 African pregnant women (501 diagnosed as HIV‐1 positive and 501 HIV‐1 negative) participating in a clinical trial program conducted in Abidjan, Côte d'Ivoire (West Africa). Hepatitis B markers studied were HBs antigen (HBsAg), and if positive, HBe antigen/anti‐HBe antibodies and HBV DNA. Two third generation (G3) HCV enzyme immunoassays (EIAs) were used for primary HCV screening. All anti‐HCV antibody‐positive sera were assessed further with supplementary assays (one another G3 EIA, RIBA 3.0, and HCV RNA). HCV genotypes were also determined. HBsAg was found in a similar proportion among HIV‐positive (45/499, 9.0%, 95% confidence interval [95% CI], 6.6–11.9) and HIV‐negative (40/498, 8.0%, 95% CI, 5.8–10.8) women (P = 0.58). The diagnosis of chronic hepatitis B, based on HBV DNA positive results, was more frequent in HIV‐positive women (26.7%), compared to HIV‐negative women (9.4%) (P = 0.06). In the case of hepatitis C infection, after supplementary testing allowing the elimination of frequent false‐positive screening results, a prevalence rate of about 1% was found, both in HIV‐positive (6/501, 1.2%, 95% CI, 0.44–2.59) and HIV‐negative (4/501, 0.8%, 95% CI, 0.22–2.03) women (P = 0.53). Of the 10 samples confirmed positive and assessed for HCV RNA, eight (80%) were viraemic and belonged to HCV genotypes 1 or 2. The relative high frequency of HIV/HBV coinfection in Côte d'Ivoire emphasises the need for monitoring the risk of hepatotoxicity by antiretroviral therapy in such patients. We propose an accurate and cost‐efficient algorithm for HCV diagnosis in Africa. J. Med. Virol. 74:34–40, 2004. © 2004 Wiley‐Liss, Inc.</abstract><qualityIndicators><score>7.408</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1772</abstractCharCount><pdfWordCount>4408</pdfWordCount><pdfCharCount>27243</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>264</abstractWordCount></qualityIndicators><title>HBV and HCV prevalence and viraemia in HIV‐positive and HIV‐negative pregnant women in Abidjan, Côte d'Ivoire: The ANRS 1236 study</title><corporate><json:item><name>for the ANRS 1236 DITRAME‐B&C Study Group</name></json:item></corporate><genre><json:string>article</json:string></genre><host><title>Journal of Medical Virology</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1096-9071</json:string></doi><issn><json:string>0146-6615</json:string></issn><eissn><json:string>1096-9071</json:string></eissn><publisherId><json:string>JMV</json:string></publisherId><volume>74</volume><issue>1</issue><pages><first>34</first><last>40</last><total>7</total></pages><genre><json:string>journal</json:string></genre></host><categories><wos><json:string>science</json:string><json:string>virology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>biomedical research</json:string><json:string>virology</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string></inist></categories><publicationDate>2004</publicationDate><copyrightDate>2004</copyrightDate><doi><json:string>10.1002/jmv.20143</json:string></doi><id>3E9C3E3ED2AF32E19C12B373783F2B62F3082F05</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/3E9C3E3ED2AF32E19C12B373783F2B62F3082F05/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/3E9C3E3ED2AF32E19C12B373783F2B62F3082F05/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/3E9C3E3ED2AF32E19C12B373783F2B62F3082F05/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">HBV and HCV prevalence and viraemia in HIV‐positive and HIV‐negative pregnant women in Abidjan, Côte d'Ivoire: The ANRS 1236 study</title></titleStmt><publicationStmt><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><licence>Copyright © 2004 Wiley‐Liss, Inc.</licence></availability><date type="published" when="2004-09"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main" xml:lang="en">HBV and HCV prevalence and viraemia in HIV‐positive and HIV‐negative pregnant women in Abidjan, Côte d'Ivoire: The ANRS 1236 study</title><title level="a" type="short" xml:lang="en">HBV and HCV Infections in African Pregnant Women</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">François</forename><surname>Rouet</surname></persName><email>rouet@aviso.ci</email><affiliation>CeDReS, CHU de Treichville, Abidjan, Côte d'Ivoire<address><country key="FR"></country></address></affiliation><affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire<address><country key="FR"></country></address></affiliation><affiliation>CeDReS, Programme PAC‐CI, CHU de Treichville, BP V3 Abidjan, Côte d'Ivoire.===</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Marie‐Laure</forename><surname>Chaix</surname></persName><affiliation>Laboratoire de Virologie, CHU Necker, EA 3620 Université René Descartes, Paris, France<address><country key="FR"></country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">André</forename><surname>Inwoley</surname></persName><affiliation>CeDReS, CHU de Treichville, Abidjan, Côte d'Ivoire<address><country key="FR"></country></address></affiliation><affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire<address><country key="FR"></country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Philippe</forename><surname>Msellati</surname></persName><affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire<address><country key="FR"></country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">Ida</forename><surname>Viho</surname></persName><affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire<address><country key="FR"></country></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">Patrice</forename><surname>Combe</surname></persName><affiliation>CeDReS, CHU de Treichville, Abidjan, Côte d'Ivoire<address><country key="FR"></country></address></affiliation><affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire<address><country key="FR"></country></address></affiliation></author><author xml:id="author-0006"><persName><forename type="first">Valériane</forename><surname>Leroy</surname></persName><affiliation>INSERM U593, ISPED, Université Victor Segalen, Bordeaux, France<address><country key="FR"></country></address></affiliation></author><author xml:id="author-0007"><persName><forename type="first">François</forename><surname>Dabis</surname></persName><affiliation>INSERM U593, ISPED, Université Victor Segalen, Bordeaux, France<address><country key="FR"></country></address></affiliation></author><author xml:id="author-0008"><persName><forename type="first">Christine</forename><surname>Rouzioux</surname></persName><affiliation>Laboratoire de Virologie, CHU Necker, EA 3620 Université René Descartes, Paris, France<address><country key="FR"></country></address></affiliation></author><author xml:id="author-0009"><author><orgName>for the ANRS 1236 DITRAME‐B&C Study Group</orgName></author></author><idno type="istex">3E9C3E3ED2AF32E19C12B373783F2B62F3082F05</idno><idno type="DOI">10.1002/jmv.20143</idno><idno type="unit">JMV20143</idno><idno type="toTypesetVersion">file:JMV.JMV20143.pdf</idno></analytic><monogr><title level="j" type="main">Journal of Medical Virology</title><title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title><idno type="pISSN">0146-6615</idno><idno type="eISSN">1096-9071</idno><idno type="book-DOI">10.1002/(ISSN)1096-9071</idno><idno type="book-part-DOI">10.1002/jmv.v74:1</idno><idno type="product">JMV</idno><imprint><biblScope unit="vol">74</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="34">34</biblScope><biblScope unit="page" to="40">40</biblScope><biblScope unit="page-count">7</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-09"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><p>A retrospective survey estimating the prevalence of hepatitis viruses B (HBV) and C (HCV) was conducted on samples taken in 1,002 African pregnant women (501 diagnosed as HIV‐1 positive and 501 HIV‐1 negative) participating in a clinical trial program conducted in Abidjan, Côte d'Ivoire (West Africa). Hepatitis B markers studied were HBs antigen (HBsAg), and if positive, HBe antigen/anti‐HBe antibodies and HBV DNA. Two third generation (G3) HCV enzyme immunoassays (EIAs) were used for primary HCV screening. All anti‐HCV antibody‐positive sera were assessed further with supplementary assays (one another G3 EIA, RIBA 3.0, and HCV RNA). HCV genotypes were also determined. HBsAg was found in a similar proportion among HIV‐positive (45/499, 9.0%, 95% confidence interval [95% CI], 6.6–11.9) and HIV‐negative (40/498, 8.0%, 95% CI, 5.8–10.8) women (<hi rend="italic">P</hi> = 0.58). The diagnosis of chronic hepatitis B, based on HBV DNA positive results, was more frequent in HIV‐positive women (26.7%), compared to HIV‐negative women (9.4%) (<hi rend="italic">P</hi> = 0.06). In the case of hepatitis C infection, after supplementary testing allowing the elimination of frequent false‐positive screening results, a prevalence rate of about 1% was found, both in HIV‐positive (6/501, 1.2%, 95% CI, 0.44–2.59) and HIV‐negative (4/501, 0.8%, 95% CI, 0.22–2.03) women (<hi rend="italic">P</hi> = 0.53). Of the 10 samples confirmed positive and assessed for HCV RNA, eight (80%) were viraemic and belonged to HCV genotypes 1 or 2. The relative high frequency of HIV/HBV coinfection in Côte d'Ivoire emphasises the need for monitoring the risk of hepatotoxicity by antiretroviral therapy in such patients. We propose an accurate and cost‐efficient algorithm for HCV diagnosis in Africa. J. Med. Virol. 74:34–40, 2004. © 2004 Wiley‐Liss, Inc.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="kwd1">HBV</term><term xml:id="kwd2">HCV</term><term xml:id="kwd3">HIV‐1 coinfection</term><term xml:id="kwd4">pregnant women</term><term xml:id="kwd5">Côte d'Ivoire</term></keywords></textClass><langUsage><language ident="EN"></language></langUsage></profileDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/3E9C3E3ED2AF32E19C12B373783F2B62F3082F05/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1096-9071</doi><issn type="print">0146-6615</issn><issn type="electronic">1096-9071</issn><idGroup><id type="product" value="JMV"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="JOURNAL OF MEDICAL VIROLOGY">Journal of Medical Virology</title><title type="short">J. Med. Virol.</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/jmv.v74:1</doi><numberingGroup><numbering type="journalVolume" number="74">74</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="2004-09">September 2004</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="6" status="forIssue"><doi origin="wiley" registered="yes">10.1002/jmv.20143</doi><idGroup><id type="unit" value="JMV20143"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><copyright ownership="publisher">Copyright © 2004 Wiley‐Liss, Inc.</copyright><eventGroup><event type="manuscriptAccepted" date="2004-04-26"></event><event type="firstOnline" date="2004-07-13"></event><event type="publishedOnlineFinalForm" date="2004-07-13"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:HeaderRef result:HeaderRef" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-20"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-30"></event></eventGroup><numberingGroup><numbering type="pageFirst">34</numbering><numbering type="pageLast">40</numbering></numberingGroup><correspondenceTo>CeDReS, Programme PAC‐CI, CHU de Treichville, BP V3 Abidjan, Côte d'Ivoire.===</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:JMV.JMV20143.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="5"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="37"></count><count type="wordTotal" number="1551"></count></countGroup><titleGroup><title type="main" xml:lang="en">HBV and HCV prevalence and viraemia in HIV‐positive and HIV‐negative pregnant women in Abidjan, Côte d'Ivoire: The ANRS 1236 study</title><title type="short" xml:lang="en">HBV and HCV Infections in African Pregnant Women</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>François</givenNames><familyName>Rouet</familyName></personName><contactDetails><email>rouet@aviso.ci</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Marie‐Laure</givenNames><familyName>Chaix</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>André</givenNames><familyName>Inwoley</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Philippe</givenNames><familyName>Msellati</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Ida</givenNames><familyName>Viho</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Patrice</givenNames><familyName>Combe</familyName></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Valériane</givenNames><familyName>Leroy</familyName></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af4"><personName><givenNames>François</givenNames><familyName>Dabis</familyName></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Christine</givenNames><familyName>Rouzioux</familyName></personName></creator><creator xml:id="au10" creatorRole="author" noteRef="#fn1"><groupName>for the ANRS 1236 DITRAME‐B&C Study Group</groupName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>CeDReS, CHU de Treichville, Abidjan, Côte d'Ivoire</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>Laboratoire de Virologie, CHU Necker, EA 3620 Université René Descartes, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="FR" type="organization"><unparsedAffiliation>INSERM U593, ISPED, Université Victor Segalen, Bordeaux, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">HBV</keyword><keyword xml:id="kwd2">HCV</keyword><keyword xml:id="kwd3">HIV‐1 coinfection</keyword><keyword xml:id="kwd4">pregnant women</keyword><keyword xml:id="kwd5">Côte d'Ivoire</keyword></keywordGroup><fundingInfo><fundingAgency>The French Agence Nationale de Recherches sur le SIDA (ANRS, Paris, France)</fundingAgency></fundingInfo><fundingInfo><fundingAgency>The French Ministry of Foreign Affairs, within the Coordinated Action AC12</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>A retrospective survey estimating the prevalence of hepatitis viruses B (HBV) and C (HCV) was conducted on samples taken in 1,002 African pregnant women (501 diagnosed as HIV‐1 positive and 501 HIV‐1 negative) participating in a clinical trial program conducted in Abidjan, Côte d'Ivoire (West Africa). Hepatitis B markers studied were HBs antigen (HBsAg), and if positive, HBe antigen/anti‐HBe antibodies and HBV DNA. Two third generation (G3) HCV enzyme immunoassays (EIAs) were used for primary HCV screening. All anti‐HCV antibody‐positive sera were assessed further with supplementary assays (one another G3 EIA, RIBA 3.0, and HCV RNA). HCV genotypes were also determined. HBsAg was found in a similar proportion among HIV‐positive (45/499, 9.0%, 95% confidence interval [95% CI], 6.6–11.9) and HIV‐negative (40/498, 8.0%, 95% CI, 5.8–10.8) women (<i>P</i> = 0.58). The diagnosis of chronic hepatitis B, based on HBV DNA positive results, was more frequent in HIV‐positive women (26.7%), compared to HIV‐negative women (9.4%) (<i>P</i> = 0.06). In the case of hepatitis C infection, after supplementary testing allowing the elimination of frequent false‐positive screening results, a prevalence rate of about 1% was found, both in HIV‐positive (6/501, 1.2%, 95% CI, 0.44–2.59) and HIV‐negative (4/501, 0.8%, 95% CI, 0.22–2.03) women (<i>P</i> = 0.53). Of the 10 samples confirmed positive and assessed for HCV RNA, eight (80%) were viraemic and belonged to HCV genotypes 1 or 2. The relative high frequency of HIV/HBV coinfection in Côte d'Ivoire emphasises the need for monitoring the risk of hepatotoxicity by antiretroviral therapy in such patients. We propose an accurate and cost‐efficient algorithm for HCV diagnosis in Africa. J. Med. Virol. 74:34–40, 2004. © 2004 Wiley‐Liss, Inc.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>The ANRS 1236 DITRAME‐B&C Study Group is organised as follows; Coordination: INSERM U 593, Université Victor Segalen, Bordeaux, France (F. Dabis); Principal investigators: Centre Hospitalier Universitaire de Yopougon, Abidjan, Côte d'Ivoire; (C. Welffens‐Ekra), Maternité Cochin Port‐Royal, Paris, France (L. Mandelbrot); Abidjan Center (Côte d'Ivoire): CeDReS, Centre Hospitalier Universitaire de Treichville (A. Inwoley, H. Menan, T. Ouassa, F. Rouet, R. Touré); Centre Hospitalier Universitaire de Yopougon (R. Camara, M. Dosso, N. Elenga, R. Likikouet, M. Timité); DITRAME Project (V. Noba, R. Ramon, I. Viho); IRD Petit Bassam (P. Msellati, local coordinator) and the Health Centers of Anonkoua‐Koute, Ouassakara, Yopougon‐Attie and Yopougon; Data management: INSERM U 593, Bordeaux (L. Dequae‐Merchadou); Methodology: INSERM U 593, Bordeaux (V. Leroy, R. Salamon); Centre Muraz/OCCGE (P. Van de Perre); Laboratoire de Virologie, Hôpital Necker‐Enfants Malades, Paris, France (C. Rouzioux).</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>HBV and HCV prevalence and viraemia in HIV‐positive and HIV‐negative pregnant women in Abidjan, Côte d'Ivoire: The ANRS 1236 study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>HBV and HCV Infections in African Pregnant Women</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>HBV and HCV prevalence and viraemia in HIV‐positive and HIV‐negative pregnant women in Abidjan, Côte d'Ivoire: The ANRS 1236 study</title></titleInfo><name type="personal"><namePart type="given">François</namePart><namePart type="family">Rouet</namePart><affiliation>CeDReS, CHU de Treichville, Abidjan, Côte d'Ivoire</affiliation><affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire</affiliation><affiliation>CeDReS, Programme PAC‐CI, CHU de Treichville, BP V3 Abidjan, Côte d'Ivoire.===</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marie‐Laure</namePart><namePart type="family">Chaix</namePart><affiliation>Laboratoire de Virologie, CHU Necker, EA 3620 Université René Descartes, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">André</namePart><namePart type="family">Inwoley</namePart><affiliation>CeDReS, CHU de Treichville, Abidjan, Côte d'Ivoire</affiliation><affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Philippe</namePart><namePart type="family">Msellati</namePart><affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ida</namePart><namePart type="family">Viho</namePart><affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Patrice</namePart><namePart type="family">Combe</namePart><affiliation>CeDReS, CHU de Treichville, Abidjan, Côte d'Ivoire</affiliation><affiliation>Programme PAC‐CI, Abidjan, Côte d'Ivoire</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Valériane</namePart><namePart type="family">Leroy</namePart><affiliation>INSERM U593, ISPED, Université Victor Segalen, Bordeaux, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">François</namePart><namePart type="family">Dabis</namePart><affiliation>INSERM U593, ISPED, Université Victor Segalen, Bordeaux, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christine</namePart><namePart type="family">Rouzioux</namePart><affiliation>Laboratoire de Virologie, CHU Necker, EA 3620 Université René Descartes, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>for the ANRS 1236 DITRAME‐B&C Study Group</namePart><description>CeDReS, CHU de Treichville, Abidjan, Côte d'IvoireProgramme PAC‐CI, Abidjan, Côte d'IvoireLaboratoire de Virologie, CHU Necker, EA 3620 Université René Descartes, Paris, FranceINSERM U593, ISPED, Université Victor Segalen, Bordeaux, France</description></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2004-09</dateIssued><dateValid encoding="w3cdtf">2004-04-26</dateValid><copyrightDate encoding="w3cdtf">2004</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">5</extent><extent unit="references">37</extent><extent unit="words">1551</extent></physicalDescription><abstract lang="en">A retrospective survey estimating the prevalence of hepatitis viruses B (HBV) and C (HCV) was conducted on samples taken in 1,002 African pregnant women (501 diagnosed as HIV‐1 positive and 501 HIV‐1 negative) participating in a clinical trial program conducted in Abidjan, Côte d'Ivoire (West Africa). Hepatitis B markers studied were HBs antigen (HBsAg), and if positive, HBe antigen/anti‐HBe antibodies and HBV DNA. Two third generation (G3) HCV enzyme immunoassays (EIAs) were used for primary HCV screening. All anti‐HCV antibody‐positive sera were assessed further with supplementary assays (one another G3 EIA, RIBA 3.0, and HCV RNA). HCV genotypes were also determined. HBsAg was found in a similar proportion among HIV‐positive (45/499, 9.0%, 95% confidence interval [95% CI], 6.6–11.9) and HIV‐negative (40/498, 8.0%, 95% CI, 5.8–10.8) women (P = 0.58). The diagnosis of chronic hepatitis B, based on HBV DNA positive results, was more frequent in HIV‐positive women (26.7%), compared to HIV‐negative women (9.4%) (P = 0.06). In the case of hepatitis C infection, after supplementary testing allowing the elimination of frequent false‐positive screening results, a prevalence rate of about 1% was found, both in HIV‐positive (6/501, 1.2%, 95% CI, 0.44–2.59) and HIV‐negative (4/501, 0.8%, 95% CI, 0.22–2.03) women (P = 0.53). Of the 10 samples confirmed positive and assessed for HCV RNA, eight (80%) were viraemic and belonged to HCV genotypes 1 or 2. The relative high frequency of HIV/HBV coinfection in Côte d'Ivoire emphasises the need for monitoring the risk of hepatotoxicity by antiretroviral therapy in such patients. We propose an accurate and cost‐efficient algorithm for HCV diagnosis in Africa. J. Med. Virol. 74:34–40, 2004. © 2004 Wiley‐Liss, Inc.</abstract><note type="funding">The French Agence Nationale de Recherches sur le SIDA (ANRS, Paris, France)</note><note type="funding">The French Ministry of Foreign Affairs, within the Coordinated Action AC12</note><subject lang="en"><genre>keywords</genre><topic>HBV</topic><topic>HCV</topic><topic>HIV‐1 coinfection</topic><topic>pregnant women</topic><topic>Côte d'Ivoire</topic></subject><relatedItem type="host"><titleInfo><title>Journal of Medical Virology</title></titleInfo><titleInfo type="abbreviated"><title>J. Med. Virol.</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0146-6615</identifier><identifier type="eISSN">1096-9071</identifier><identifier type="DOI">10.1002/(ISSN)1096-9071</identifier><identifier type="PublisherID">JMV</identifier><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>74</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>34</start><end>40</end><total>7</total></extent></part></relatedItem><identifier type="istex">3E9C3E3ED2AF32E19C12B373783F2B62F3082F05</identifier><identifier type="DOI">10.1002/jmv.20143</identifier><identifier type="ArticleID">JMV20143</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2004 Wiley‐Liss, Inc.</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000918 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000918 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:3E9C3E3ED2AF32E19C12B373783F2B62F3082F05
|texte= HBV and HCV prevalence and viraemia in HIV‐positive and HIV‐negative pregnant women in Abidjan, Côte d'Ivoire: The ANRS 1236 study
}}
| This area was generated with Dilib version V0.6.31. |  |